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Abstract The aim of present study is to prepare microspheres of eudragit 
RL 100 loaded with Nefopam Hydrochloride by single emulsion solvent 
evaporation technique. Taguchi L9 orthogonal array design has been used 
to optimize the composition and operating conditions for preparation of 
formulations. Nine batches (F1-F9) were prepared by taking three independent 
variables (X
1
- drug: polymer ratio, X
2
- stirring speed and X
3
- stirring time) 
at three levels (+1, 0, -1). Response variables studied for batches (F1-F9) 
were mean particle size (µm) (Y
1
), drug entrapment efficiency (% w/w) (Y
2
) 
and drug loading (% w/w) (Y
3
). Drug- polymer compatibility study was 
carried out by DSC and FTIR spectroscopy and indicates no physicochemical 
interaction. Microspheres were analyzed for morphological characteristics, 
mean particle size, drug entrapment efficiency, drug loading and in-vitro drug 
release. Percentage cumulative drug release for optimized batch F5 was found 
to be 85.421 ± 0.054 and followed higuchi model for release of drug. 
Keywords: Taguchi, Response Variables, Independent Variables, 
Drug Entrapment Efficiency, Drug Loading, Higuchi Model.
1. INTRODUcTION
An ideal drug delivery system should be able to deliver effective amount of the drug for a sufficient period of time. Polymeric microsphere is an ideal formulation for sustained drug delivery (Neelesh et. al., 2004; 
Saharan et. al., 2009; Kumar and Majeti, 2000). Such systems offer numerous 
advantages over traditional methods of drug delivery including tailoring of 
drug release rates, protection of fragile drugs, increased bioavailability of 
drugs, decreased frequency of administration and increased patient comfort and 
compliance (Kumar et. al., 2011; Prasanth et. al., 2011; Gholap et. al., 2010).
Statistical experimental designs provide a coherent plan for carrying 






Factorial design, response surface methodology and taguchi design are 
frequently applied experimental designs (Lewis et. al., 2005; Myers et. al., 
2003). Taguchi design can optimize many factors simultaneously and extract 
more quantitative information by performing only a few experimental trials 
(Varshosaz et. al., 2009; Taguchi, 1987). Optimization of process implies 
the use of an experimental design in order to identify factors affecting the 
formulation, determine levels of factor resulting in an optimum response and 
decrease variability in process without presiding over or excluding causes of 
variation. Optimization of process parameters by taguchi design is an effort 
to minimize the variation in quality as well as to attain the quality near to the 
intended value simultaneously (Jose et. al., 2012).
Nefopam Hydrochloride is a centrally acting non-opioid analgesic and anti-
inflammatory drug of the Benzoxazocine class having 30-40% bioavailability, 
high local and systemic gastro-intestinal disturbances and high first pass 
metabolism. It has an absorption region from upper gastro intestinal tract and 
an elimination half-life of 3.5 h (Aymard et. al., 2003; Alfonsi et. al., 2004; Del 
et. al., 2009; Starek et. al., 2011). It has log P value 3.519 which contribute to 
lipid solubility and hydrophilicity. It is used for the relief of acute and chronic 
pain. 
The aim of present research work is to prepare microspheres of eudragit 
RL 100 loaded with Nefopam Hydrochloride using taguchi L9 orthogonal 
array design by single emulsion solvent evaporation technique to obtain 
sustained release of drug. Nine batches (F1-F9) were prepared by taking three 
independent variables (X
1
- drug: polymer ratio, X
2
- stirring speed and X
3
- 
stirring time) at three levels (+1, 0, -1). 
2. MATERIALS AND METHODOLOGY
2.1 Materials
Nefopam Hydrochloride was purchased from Prince Scientific and Surgical, 
Hyderabad. Eudragit RL100 was obtained as a gift sample from Evonik 
Industries AG, Mumbai, India. Light liquid paraffin, n-hexane and acetone 
were obtained from Merck Specialties Private Limited, Mumbai. Magnesium 
Stearate and methanol were obtained from Loba Chemicals Private Limited, 
Mumbai, India. 
2.2 Experimental Design and Analysis
Taguchi orthogonal array L9 design was used to optimize the composition 








study were drug: polymer ratio, stirring speed and stirring time taken at low, 
medium and high levels are given in Table 1.
Response variables studied for prepared batches were mean particle 
size (µm) (Y
1
), drug entrapment efficiency (% w/w) (Y
2
) and drug loading 
(% w/w) (Y
3
) are given in Table 2. Taguchi design layout with coded values 
of independent variables is given in Table 3. The experimental trials were 
performed in random order.
Table 1: Levels of Independent VarIables
S. No. Independent Variables
codes
 -1(Low) 0 (Medium) 
+1 (High) 
1. Drug: ERL (w/w), X
1
1:2 500 2
2. Stirring Speed, (rpm), X
2
1:3 1000 3
3. Stirring Time (hrs), X
3
1:4 1500 4
Table 2: Response variables
 S. No. codes Response variables 
1. Y
1
Mean Particle Size (µm)
2. Y
2
Drug Entrapment Efficiency (% w/w)
3. Y
3
Drug Loading (% w/w)
Nine batches of microspheres (F1-F9) were prepared as per experimental 
design layout of taguchi L9 orthogonal array design. Calculations and statistical 
analysis of the results were carried out by multiple linear regression analysis 
(MLRA) to determine which factors has statistically significant effect on the 
response parameters.
2.3 Methods
2.3.1 Preparation of Microspheres
Single emulsion solvent evaporation technique was selected for preparation 






microspheres from preformed polymers and due to its relative ease. Moreover, 
selected drug and polymer are soluble in a common solvent and drug polymer 
Nefopam Hydrochloride and eudragit RL 100 (1:2, 1:3 and 1:4), were 
dissolved in mixture of methanol and acetone (1:1). This mixture was stirred 
with magnetic stirrer to produce a transparent solution. Drug-polymer solution 
was slowly added with continuous stirring by a magnetic stirrer to light liquid 
paraffin taken as continuous phase containing span 60 (0.1% w/v) as an 
emulsifier. Prepared microspheres were filtered and washed with petroleum 
ether. Successive washings were continued till all the organic solvent was 
removed. Microspheres were lyophilized and stored till further use (Das and 
Das, 1998; Lee et. al., 2000; Phutane et. al., 2010). 
2.3.2 Mean Particle Size Analysis 
Particle size distribution of prepared microspheres was measured in a particle 
size analyzer by laser diffraction (Mastersizer, Malvern Instruments, United 
Kingdom). Approximately 10 mg of microspheres were suspended in deionised 
water and sonicated with an ultra-sound probe for 1 min. This homogeneous 
suspension was determined for equivalent volume diameter. Measurements for 
particle size were taken in triplicate (Srivastava et. al., 2005).
2.3.3 Drug Entrapment Efficiency (%) 
Accurately weighed 100 mg of microsphere was extracted in 100 ml phosphate 
buffer, pH 7.4 for 24 h. Extracted solution was filtered and a sample of 5 ml 
Table 3: Experimental design layout as per taguchi L9 orthogonal array design





F1 -1 -1 -1
F2 -1  0  0
F3 -1 +1 +1
F4  0 -1  0
F5  0  0 +1
F6  0 +1 -1
F7 +1 -1 +1
F8 +1  0 -1








was withdrawn from this solution. Sample was diluted to 50 ml with distilled 
water and assayed spectrophotometrically (Systronics AU2701) at 266 nm 
to determine the content of Nefopam Hydrochloride in microsphere. All the 
determinations were performed in triplicate (Arindam and Biswanath, 2006). 
Drug entrapment efficiency (%) of the microspheres was calculated using the 
equation:
 Drug Encapsulation Efficiency (%) = Drug Content × 100 Weight of drug  
2.3.4 Loading Efficiency (%)
Accurately weighed 100 mg of microsphere was extracted in 100 ml phosphate 
buffer, pH 7.4 for 24 h. Extracted solution was filtered and a sample of 5 ml 
was withdrawn from this solution. Sample was diluted to 50 ml with distilled 
water and assayed spectrophotometrically (Systronics AU2701) at 266 nm 
to determine the content of Nefopam Hydrochloride in microsphere. All the 
determinations were performed in triplicate (Arindam and Biswanath, 2006). 
Drug Loading (%) of the microspheres was calculated using the equation:
 Drug Loading (%) = Drug Content × 100 Weight of Drug + Polymer 
2.3.5 Statistical analysis
Response variables were analyzed using Microsoft Excel spreadsheet, 2007. 
Multiple linear regression analysis was used to develop equations for mean 
particle size (Y
1
), % drug entrapment efficiency (Y
2




 Y= β0 + β1X1 + β2X2 + β3X3 
Where, Y is estimated response of response variable, β
0 
is arithmetic mean 
response of nine batches, β
1 













estimated coefficient for factor X
3.
 
2.3.6 Differential scanning Calorimetry
Differential scanning calorimetry measurements were done on DSC Q10V 9.0 
build 275 model Water Limited instrument by heating the samples from 25 oC 
to 250 oC at the rate of 20 oC /minute in a nitrogen atmosphere (flow rate, 10 
mL/min). 






FTIR spectra were taken on FTIR- Shimadzu instrument to investigate the 
possible chemical interactions between drug and polymer. 1 mg of sample was 
triturated with 300 mg of KBr in a mortar. A little amount of triturated sample 
was compressed at 10 kg/cm2 into a pellet maker. Pellet was kept on sample 
holder and scanned from 4000 cm-1 to 400 cm-1. 
2.3.8. In-vitro dissolution studies
In-vitro dissolution studies were performed on microspheres at 37oC (± 0.5oC) 
at 100 rpm with USP Dissolution Apparatus II (LABINDIA DF 8000). An 
accurately weighed amount of microspheres was dispersed in dissolution 
media consisting of 900 ml Phosphate buffer, pH 7.4 and dissolution study 
was carried for 24 h. Aliquots of dissolution fluid was withdrawn at stated 
time intervals to assay the released drug spectrophotometrically at 266 nm. 
Each graphical data point was mean of dissolution data from three samples. 
Corrections were made for withdrawal of samples (Srivastava et. al., 2005; 
Arindam and Biswanath, 2006; Umer et. al., 2011; Barratt, 2000).
2.3.9 Scanning Electron Microscopic Analysis
Microspheres were plated with gold palladium for 150 seconds to achieve a 20 
nm film under an atmosphere of air (Coater Polaron, 18mA current at 1.4 kV). 
Coated sample was examined using scanning electron microscope (Variable 
Pressure Scanning Electron Microscope, Hitachi S3400N). Spherical shape of 
microspheres was established by SEM. 
3. RESULTS AND DIScUSSION 
Taguchi L9 orthogonal array design was used to prepare microspheres of 
eudragit RL 100 loaded with Nefopam Hydrochloride by single emulsion solvent 
evaporation technique to obtain a sustained release of drug. Microspheres were 
prepared to study the effect of drug polymer ratio, stirring speed and stirring 
time on response variables of microspheres. Nine formulations (F1–F9) were 
developed and calculated values of response variables are shown in Table 4. 







can be depicted mathematically as; 
Y
1
 = 122.2 + 45.29 X
1






 = 62.76+ 7.94 X
1







 = 15.96 – 1.68 X
1




From values of coefficients of linear equations, it was concluded that mean 








decreased with the increase in stirring speed and stirring time. Drug entrapment 
efficiency (% w/w) was increased with the increase in drug-polymer ratio, 
stirring speed and stirring time. Drug loading (% w/w) was decreased with the 
increase in drug-polymer ratio whereas increased with the increase in stirring 
speed and stirring time. Formulation (F5) was found to be the optimized batch 
with mean particle size (100.38 ± 1.12 µm), drug entrapment efficiency (78.02 
± 0.99 % w/w) and drug loading (19.50± 0.55 % w/w). 
3.1 Differential scanning calorimetry
DSC studies were performed to investigate physicochemical interaction 
between drug and polymer. DSC thermograms of pure Nefopam hydrochloride, 
eudragit RL 100 and mixture of drug with eudragit RL 100 were evaluated. 
Peak corresponding to t
m
 of Nefopam Hydrochloride was present in 
the mixture of drug and polymer indicating absence of physicochemical 
interaction between Nefopam Hydrochloride and eudragit RL 100. DSC 
thermograms of Nefopam Hydrochloride, Eudragit RL 100 and mixture of 
Nefopam Hydrochloride and eudragit RL 100 are given in Figure 1 (a), 1 (b) 
and 1 (c) respectively.
3.2 Fourier Transform Infra-red Spectroscopy
FTIR studies were performed to investigate physicochemical interaction 
between drug and polymer. FTIR spectra of pure Nefopam Hydrochloride and 
mixture of drug with eudragit RL 100 were evaluated. Characteristic peaks of 














F1 -1 -1 -1 85.43 46.12 15.37
F2 -1 0 0 80.33 53.11 17.70
F3 -1 +1 +1 75.65 48.22 16.07
F4 0 -1 0 140.42 68.11 17.03
F5 0 0 +1 100.38 78.02 19.50
F6 0 +1 -1 104.42 76.11 19.02
F7 +1 -1 +1 180.23 65.43 13.08
F8 +1 0 -1 172.41 67.23 13.44






drug were observed at 3429 cm-1 (C-O-C of cyclic ring), 2910 cm-1 (C-H(s) of 
alkane), 1446 cm-1 (C=C of aromatics), 1346 cm-1 (C-N of amines) and 759 cm-1 
(aromatic ring). It was found that there was neither shifting nor overlapping of 
characteristic peaks of drug in FTIR spectra of mixture of drug with eudragit 
RL 100 which indicates absence of physicochemical interaction between drug 
and polymer. FTIR spectra of Nefopam Hydrochloride and mixture of drug 
with eudragit RL 100 are given in Figure 2 and Figure 3 respectively.
Figure 1: DSC thermogram of (a) Pure Nefopam Hydrochloride (b) Eudragit 
RL 100 (c) Mixture of Nefopam Hydrochloride and eudragit RL 100
Figure 2: FTIR Spectra of Nefopam Hydrochloride 
3.3 In-vitro dissolution studies
In-vitro drug release studies were performed for pure drug, batch F5 and F6 
in phosphate buffer, pH 7.4. Batch F5 was found to be optimized batch which 








which gives 80.342 ± 0.032 % release in 24 hours. In-vitro drug release pattern 
of pure drug, batch F5 and batch F6 is given in Figure 4.
In-vitro drug release data of optimized batch F5 was fitted to classic drug-
release kinetics models such as zero-order model (% release vs. t), first order 
model (log% release vs. t), higuchi model (M
t




n) (Costa et. al., 2001). Microsphere release mechanisms 
were assessed by comparing regression coefficients (r2). Regression coefficient 
value for higuchi model was found to be 0.968. Drug release was shown to 
follow a higuchi model, with the release mechanism apparently controlled by a 
rapid diffusion-release process rather than polymer degradation. Higuchi plot 
of optimized batch F5 is given in Figure 5.
Figure 3: FTIR Spectra of mixture of Nefopam Hydrochloride and eudragit 
RL 100






Figure 5: Higuchi plot of the optimized batch F5
Figure 6: SEM Image of optimized batch F5 of microspheres loaded with 
Nefopam Hydrochloride 
3.4 Scanning electron microscopic (SEM)
Morphology of optimized batch F5 was examined by using scanning electron 
microscopy. SEM has been used to determine texture and examine morphology 
of surface. SEM study revealed that microspheres were spherical in shape 
shown in Figure 6.
4. cONcLUSION
From the results of study, it was concluded that single emulsion solvent 








Nefopam Hydrochloride using Eudragit RL 100 as matrix polymer. Microspheres 
were developed using taguchi L9 orthogonal array design. These investigations 
provided an understanding of the effects of drug-polymer ratio, stirring speed 
and stirring time on mean particle size, drug entrapment efficiency and drug 
loading. From the values of the coefficients of the linear equations developed 
by multiple linear regressions analysis, it was concluded that mean particle 
size (µm) increased with increase in drug-polymer ratio whereas decreased 
with increase in stirring speed and stirring time. Drug entrapment efficiency 
(% w/w) increased with increase in drug-polymer ratio, stirring speed and 
stirring time. Drug loading (% w/w) decreased with increase in drug-polymer 
ratio whereas increased with increase in stirring speed and stirring time. Based 
on the above findings, it was concluded that batch F5 with mean particle size 
(100.38 ± 1.12 µm), drug entrapment efficiency (78.02 ± 0.99 % w/w) and 
drug loading (19.50± 0.55 % w/w) was optimized formulation of microsphere. 
From in-vitro drug release studies, it was found that the optimized batch F5 
gives sustained release of drug. In-vitro drug release data of batch F5 was fitted 
in various drug release kinetic models and it was found that it was best fitted in 
higuchi model with regression coefficient value 0.968. Spherical shape surface 
morphology of microspheres was confirmed by SEM. It was concluded that a 
sustained release microspheres of Nefopam Hydrochloride were successfully 
prepared using eudragit RL 100 by single emulsion solvent evaporation 
technique with the selection of appropriate experimental conditions. Prepared 
microsphere can be administered into a suitable capsule dosage form by filling 
powdered microsphere containing equivalent therapeutic dose of Nefopam 
Hydrochloride into hard gelatin capsule shell.
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